Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension study of AOC 1001 in myotonic dystrophy type 1
NL-OMON59139Phase 3Recruiting
- Sponsor
- Avidity Biosciences
- Start
- Jan 2026
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of delpacibart etedesiran in myotonic dystrophy type 1 (DM1), sponsored by Avidity Biosciences. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jan 2026; status: recruiting.
02
Drugs
delpacibart etedesiran
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NL-OMON59139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59139.